Mga Batayang Estadistika
| LEI | 5493003Q78Q8VKGF1459 |
| CIK | 1512717 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Theratechnologies Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Addres |
|
| September 5, 2025 |
EX-99.1 Exhibit 99.1 Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, September 5, 2025 (GLOBE NEWS |
|
| September 2, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Addres |
|
| September 2, 2025 |
EX-99.1 Exhibit 99.1 Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak • Your vote is important regardless of the number of Shares you own. • Board unanimously recommends shareholders vote “FOR” the Arrangement. • Shareholders are encouraged to review the circular carefully and submit t |
|
| August 18, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address o |
|
| August 18, 2025 |
EX-99.3 Exhibit 99.3 320 Bay Street, 14th Floor Toronto, ON M5H 4A6 www.computershare.com 000001 Mr A Sample Designation (if any) Security Class Add1 Common Shares Add2 add3 Holder Account Number add4 add5 C1234567890 XXX add6 Fold Form of Proxy—Special Meeting of Shareholders to be held on September 12, 2025 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. shareho |
|
| August 18, 2025 |
EX-99.1 Exhibit 99.1 Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak • Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per sha |
|
| August 18, 2025 |
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS EX-99.1 Exhibit 99.1 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT, pursuant to an interim order of the Superior Court of Québec dated August 8, 2025 (as the same may be amended, the “Interim Order”), a special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (the “Shares”) of Theratechnologies Inc. (the “Corporation”) will be held in a hybrid fo |
|
| August 18, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address o |
|
| August 18, 2025 |
EX-99.2 Table of Contents Exhibit 99.2 These materials are important and require your immediate attention. They require shareholders of Theratechnologies Inc. to make important decisions. If you are in doubt as to how to make such decisions, please contact your financial, legal, tax or other professional advisor. If you are a shareholder of Theratechnologies Inc. and have any questions regarding t |
|
| August 18, 2025 |
EX-99.4 Exhibit 99.4 VOTING INSTRUCTION FORM THERATECHNOLOGIES INC. MEETING TYPE: Special Meeting MEETING DATE: Friday, September 12, 2025 at 10:00 A.M. EDT RECORD DATE: For holders as of August 13, 2025 PROXY DEPOSIT DATE: September 10, 2025 A/C 88338H704 ** ISSUER COPY ** STEP 1 REVIEW YOUR VOTING OPTIONS ONLINE: Vote at proxyvote.com using your computer or mobile data device. SCAN TO VIEW MATER |
|
| August 18, 2025 |
LETTER OF TRANSMITTAL FOR REGISTERED HOLDERS OF COMMON SHARES OF THERATECHNOLOGIES INC. EX-99.5 Exhibit 99.5 Please read the management information circular including the appendices attached thereto, dated August 12, 2025 (the “Circular”) mailed to holders (“Shareholders”) of common shares (“Shares”) of Theratechnologies Inc. (the “Corporation”) and the instructions attached hereto carefully before completing this letter of transmittal (“Letter of Transmittal”). If Shares are registe |
|
| July 18, 2025 |
Exhibit 99.1 July 18, 2025 650 de Maisonneuve W Blvd, 7th floor Montreal QC, H3A 3T2 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: THERATECHNOLOGIES INC Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special Meeting Record Date for Notice of Meeting : August 13, 2025 Re |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of prin |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of prin |
|
| July 10, 2025 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street Suite 1100 Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE July 2, 2025 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on July 2, 2025 via “GLOBE NEWSWIRE”. A copy |
|
| July 9, 2025 |
EX-99.10 Exhibit 99.10 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrang |
|
| July 9, 2025 |
EX-99.8 Exhibit 99.8 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
EX-99.11 Exhibit 99.11 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrang |
|
| July 9, 2025 |
EX-99.1 Exhibit 99.1 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
EX-99.3 Exhibit 99.3 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies, Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrange |
|
| July 9, 2025 |
EX-99.7 Exhibit 99.7 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of prin |
|
| July 9, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended May 31, 2025. 2. No misrepresentati |
|
| July 9, 2025 |
EX-99.12 Exhibit 99.12 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrang |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of prin |
|
| July 9, 2025 |
EX-99.4 Exhibit 99.4 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended May 31, 2025. |
|
| July 9, 2025 |
Exhibit 99.1 Theratechnologies Reports Financial Results for the Second Quarter 2025 ● Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025 ● Positive Adjusted EBITDA1 for the fifth straight quarter ● Subsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak Montreal – July 9, 2025 – |
|
| July 9, 2025 |
EX-99.6 Exhibit 99.6 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of |
|
| July 9, 2025 |
FUTURE PAK, LLC CB BIOTECHNOLOGY, LLC THERATECHNOLOGIES INC. ARRANGEMENT AGREEMENT JULY 2, 2025 Exhibit 99.1 EXECUTION VERSION FUTURE PAK, LLC and CB BIOTECHNOLOGY, LLC and THERATECHNOLOGIES INC. ARRANGEMENT AGREEMENT JULY 2, 2025 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 3 Section 1.1 Defined Terms 3 Section 1.2 Certain Rules of Interpretation 23 ARTICLE 2 THE ARRANGEMENT 24 Section 2.1 Arrangement 24 Section 2.2 Interim Order 24 Section 2.3 Meeting 25 Section 2.4 Circular 27 Section 2.5 F |
|
| July 9, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of |
|
| July 9, 2025 |
Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three- and six-month periods ended May 31, 2025 and 2024 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Income (Lo |
|
| July 9, 2025 |
EX-99.2 Exhibit 99.2 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE-AND SIX-MONTH PERIODS ENDED MAY 31, 2025 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three- and six-month periods ended May 31, 2025, compared to the three- and six-month p |
|
| July 9, 2025 |
EX-99.9 Exhibit 99.9 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 9, 2025 |
EX-99.5 Exhibit 99.5 SUPPORT AND VOTING AGREEMENT July 2, 2025 TO: CB BIOTECHNOLOGY, LLC Dear Sirs/Madams: Re: Support and Voting Agreement The undersigned understands that CB Biotechnology, LLC (the “Purchaser”), Future Pak, LLC and Theratechnologies Inc. (the “Company”) wish to enter into an arrangement agreement dated as of the date hereof (the “Arrangement Agreement”) contemplating an arrangem |
|
| July 3, 2025 |
EX-99.1 Exhibit 99.1 Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak • Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share • Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior t |
|
| July 3, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of |
|
| May 29, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of p |
|
| May 29, 2025 |
Theratechnologies Reports on its Annual Meeting of Shareholders EX-99.1 Exhibit 99.1 Theratechnologies Reports on its Annual Meeting of Shareholders MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect t |
|
| May 2, 2025 |
Exhibit 99.3 Thera technologies Computershare 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class COMMON SHARES Holder Account Number Fold Form of Proxy - Annual Meeting of Shareholders to be held on May 29, 2025 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or com |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of princ |
|
| May 2, 2025 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To the shareholders of Theratechnologies Inc. (the “Corporation”): NOTICE IS HEREBY GIVEN that an annual meeting of shareholders (the “Meeting”) of the Corporation will be conducted online only through a live audio webcast at https://meetnow.global/MTPTSMV on Thursday, May 29, 2025, at 10:00 a.m. (Eastern Time) for the following purposes: (1) t |
|
| May 2, 2025 |
Table of Contents Exhibit 99.2 MANAGEMENT PROXY CIRCULAR The information contained in this management proxy circular (the “Circular”) is given as at April 29, 2025, except as otherwise noted. In this Circular, the symbol “$” refers to the American dollar and the symbol “CAN $” or “CAD” refers to the Canadian dollar. Table of Contents TABLE OF CONTENTS ITEM I. INFORMATION RELATING TO VOTING 1 Who i |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| April 16, 2025 |
Theratechnologies Provides Update on Sale Process Exhibit 99.1 Theratechnologies Provides Update on Sale Process Montreal, Canada – April 15, 2025 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of |
|
| April 15, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of |
|
| April 15, 2025 |
and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company Exhibit 99.1 Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company Montreal, Canada – April 11, 2025 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press releas |
|
| April 9, 2025 |
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements Exhibit 99.1 Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements ● FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy ● Total Revenue $19 million, representing +17% growth year over year ● FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA ● Latest from VAMOS study demo |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| April 9, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2025 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three-month period ended February 28, 2025, compared to the three-month period ended February 29, |
|
| April 9, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended February 28, 2025. 2. No misreprese |
|
| April 9, 2025 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended February 28, 2025. 2. |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| April 9, 2025 |
Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three-month periods ended February 28, 2025 and February 29, 2024 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive I |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| April 8, 2025 |
Exhibit 99.1 Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA WR™ MONTREAL, April 8, 2025 (GLOBE NEWSWIRE) – Theratechnologies Inc. (“Theratechnologies” or th |
|
| April 1, 2025 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE March 25, 2025 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on March 25, 2025 via “GLOBE NEWSWIRE”. A |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of pri |
|
| March 26, 2025 |
Exhibit 99.1 Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today a |
|
| February 26, 2025 |
PERSONAL AND CONFIDENTIAL Exhibit 4.35 Montreal, December 23, 2024 John Leasure Global Commercial Officer Theratechnologies Inc. RE: Amendment to your Employment Agreement – Long-Term Incentive Compensation Value Dear John: I am pleased to inform you that, as part of the annual review of the total annual compensation paid to executive officers, including the long-term incentive compensation pl |
|
| February 26, 2025 |
Exhibit 4.29 OFFICE LEASE AGREEMENT BETWEEN CENTURIAN PEEL/METCALFE PROPERTIES INC. (the “Landlord”) AND THERATECHNOLOGIES INC. (the “Tenant”) Initials Landlord Tenant OFFICE LEASE TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS, INTENT AND INTERPRETATION 3 1.1 Definitions 3 1.2 Intent 6 1.3 Freely Negotiated 7 ARTICLE II LEASE 7 2.1 Lease of Premises 7 2.2 Base Building Work and Defects |
|
| February 26, 2025 |
LICENSE AGREEMENT IONIS PHARMACEUTICALS, INC. THERATECHNOLOGIES INC. Dated December 03, 2024 Exhibit 4.32 CONFIDENTIAL Execution Version LICENSE AGREEMENT BETWEEN IONIS PHARMACEUTICALS, INC. AND THERATECHNOLOGIES INC. Dated December 03, 2024 CONFIDENTIAL Execution Version TABLE OF CONTENTS ARTICLE 1 OVERVIEW 1 1.1 Development and Commercialization 1 1.2 Governance 1 1.3 Purpose 1 ARTICLE 2 LICENSES 2 2.1 License Grants to Thera 2 2.2 License Grant to Ionis 3 2.3 Sublicensing and Subcontra |
|
| February 26, 2025 |
[TRANSLATION] Exhibit 4.33 PERSONAL AND CONFIDENTIAL Montreal, December 23, 2024 Christian Marsolais Senior Vice-President and Chief Medical Officer Theratechnologies Inc. RE: Amendment to your Employment Agreement – Long-Term Incentive Compensation Value Dear Christian: I am pleased to inform you that, as part of the annual review of the total annual compensation paid to executive officers, i |
|
| February 26, 2025 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 (“Exchange Act”) As of the date of the Annual Report on Form 20-F of which this Exhibit 2.3 is a part, Theratechnologies Inc. (“Company”, “Corporation”, “we” or “us”) had the following securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Nam |
|
| February 26, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EX-12.1 Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Paul Lévesque, certify that: 1. I have reviewed this annual report on Form 20-F of Theratechnologies Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 26, 2025 |
Exhibit 4.28 LOGISTICS SERVICES AGREEMENT BY AND BETWEEN THERATECHNOLOGIES, INC. (“SUPPLIER”) AND McKESSON SPECIALTY CARE DISTRIBUTION LLC (“PROVIDER”) CONTENTS ARTICLE I: INTERPRETATION AND DEFINITIONS 3 ARTICLE II: SCOPE OF SERVICES 8 ARTICLE III: THE SERVICES TO BE PERFORMED BY PROVIDER 9 ARTICLE IV: SHIPPING AND DATA REPORTING 14 ARTICLE V: GOVERNMENT APPROVALS AND COMPLIANCE 16 ARTICLE VI: TE |
|
| February 26, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| February 26, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Theratechnologies Inc. |
|
| February 26, 2025 |
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 Exhibit 99.1 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 ● Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million ● Achieved record quarterly revenue of $25 million and annual revenue of $85.9 million ● New credit facilities’ favorable interest rates and am |
|
| February 26, 2025 |
[TRANSLATION] Exhibit 4.34 PERSONAL AND CONFIDENTIAL Montreal, December 23, 2024 Jocelyn Lafond General Counsel and Corporate Secretary Theratechnologies Inc. RE: Amendment to your Employment Agreement – Long-Term Incentive Compensation Value Dear Jocelyn: I am pleased to inform you that, as part of the annual review of the total annual compensation paid to executive officers, including the lo |
|
| February 26, 2025 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EX-12.2 Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Philippe Dubuc, certify that: 1 I have reviewed this annual report on Form 20-F of Theratechnologies Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 26, 2025 |
- 1 - [TRANSLATION] Exhibit 4.30 Counterpart Execution CREDIT AGREEMENT dated November 27, 2024; BETWEEN: INVESTISSEMENT QUÉBEC, a legal person governed by the Act respecting Investissement Québec (Québec), having its head office at 1195 Lavigerie Ave.(Édifice Iberville 1), Suite 060, Québec City, Québec, G1V 4N3 and a place of business at 1001 Robert-Bourassa Blvd., Suite 1000, Montréal (Québec) |
|
| February 26, 2025 |
EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES–OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Theratechnologies Inc. (the “Company”) for the fiscal year ended November 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philippe Dubuc, Senior Vice Presi |
|
| February 26, 2025 |
LOGISTICS SERVICES AGREEMENT BY AND BETWEEN THERATECHNOLOGIES, INC. RxCROSSROADS 3PL LLC Exhibit 4.27 LOGISTICS SERVICES AGREEMENT BY AND BETWEEN THERATECHNOLOGIES, INC. (“SUPPLIER”) AND RxCROSSROADS 3PL LLC (“PROVIDER”) Contents ARTICLE I: INTERPRETATION AND DEFINITIONS 3 ARTICLE II: SCOPE OF SERVICES 7 ARTICLE III: THE SERVICES TO BE PERFORMED BY PROVIDER 8 ARTICLE IV: SHIPPING AND DATA REPORTING 13 ARTICLE V: GOVERNMENT APPROVALS AND COMPLIANCE 15 ARTICLE VI: PAYMENT; TAXES 16 AR |
|
| February 26, 2025 |
EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES–OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Theratechnologies Inc. (the “Company”) for the fiscal year ended November 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Lévesque, President and Chie |
|
| February 26, 2025 |
[TRANSLATION] Exhibit 4.37 PERSONAL AND CONFIDENTIAL Montreal, December 23, 2024 Philippe Dubuc Senior Vice-President and Chief Financial Officer Theratechnologies Inc. RE: Amendment to your Employment Agreement – Long-Term Incentive Compensation Value Dear Philippe: I am pleased to inform you that, as part of the annual review of the total annual compensation paid to executive officers, includ |
|
| February 26, 2025 |
PERSONAL AND CONFIDENTIAL Exhibit 4.36 Montreal, December 23, 2024 Paul Lévesque President and CEO Theratechnologies Inc. RE: Amendment to your Employment Agreement – Long-Term Incentive Compensation Value Dear Paul: I am pleased to inform you that, as part of the annual review of the total annual compensation paid to executive officers, including the long-term incentive compensation plan (“LTI |
|
| February 26, 2025 |
Exhibit 4.31 CREDIT AGREEMENT dated as of November 27, 2024 among THERATECHNOLOGIES INC. as Borrower and THE TORONTO-DOMINION BANK as Administrative Agent, Lead Arranger and Bookrunner and THE FINANCIAL INSTITUTIONS PARTY FROM TIME TO TIME TO THIS AGREEMENT as Lenders SENIOR SECURED CREDIT FACILITIES DENTONS CANADA LLP TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 Section 1.1 Definitions 1 Section |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025. Commission File Number 001-35203 Theratechnologies Inc. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montreal, Quebec H3A 1T8, Canada (Address of |
|
| February 21, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 21, 2025 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal |
|
| February 21, 2025 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE February 13, 2025 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on February 13, 2025 via “GLOBE NEWSWIR |
|
| February 14, 2025 |
Theratechnologies Resumes Distribution of EGRIFTA SV® EX-99.1 2 d873634dex991.htm EX-99.1 Exhibit 99.1 Theratechnologies Resumes Distribution of EGRIFTA SV® MONTREAL, February 13, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care, today announ |
|
| February 14, 2025 |
6-K 1 d873634d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 14, 2025 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 ( |
|
| February 14, 2025 |
Exhibit 99.1 Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update MONTREAL, February 14, 2025 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards o |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 14, 2025 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 January 10, 2025 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| January 10, 2025 |
Theratechnologies Provides Update on EGRIFTA SV® Supply Exhibit 99.1 Theratechnologies Provides Update on EGRIFTA SV® Supply MONTREAL, January 9, 2025 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the pat |
|
| December 19, 2024 |
Exhibit 99.1 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment MONTREAL, December 18, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has sub |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 19, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| December 12, 2024 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE December 4, 2024 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on December 4, 2024 via “GLOBE NEWSWIRE” |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 12, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 11, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| December 11, 2024 |
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Exhibit 99.1 Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA MONTREAL, Dec., 10, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Ad |
|
| December 9, 2024 |
Exhibit 991 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with complete resolution of a liver lesion MONTREAL, December 9, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 9, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| December 5, 2024 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE December 2, 2024 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on December 2, 2024 via “GLOBE NEWSWIRE” |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 5, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 4, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| December 4, 2024 |
Theratechnologies Announces Resumed Production of EGRIFTA SV® Exhibit 99.1 Theratechnologies Announces Resumed Production of EGRIFTA SV® MONTREAL, December 3, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the production of EGRIFTA SV® has resumed following a voluntary shut |
|
| December 4, 2024 |
Exhibit 99.1 Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, December 4, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (T |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 4, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| December 2, 2024 |
6-K 1 d880078d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 2, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (A |
|
| December 2, 2024 |
Exhibit 99.1 Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec ● New financing replaces existing credit facility to optimize Company’s capital structure ● Favorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to support business development strategy MONTREAL, December 2, 2024 (GLOBE NEWSWIR |
|
| November 26, 2024 |
Exhibit 99.1 Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy MONTREAL, November 26, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Ther |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 November 26, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended August 31, 2024. 2. No |
|
| October 10, 2024 |
Exhibit 99.1 Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024 • Q3 revenue of $22.6 million represents +8% growth year-over-year • Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million • Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to |
|
| October 10, 2024 |
Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three- and nine-month periods ended August 31, 2024 and 2023 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended August 31, 2024. 2. No misrepresent |
|
| October 10, 2024 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE-AND NINE-MONTH PERIODS ENDED AUGUST 31, 2024 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three- and nine-month periods ended August 31, 2024, compared to the three- and nin |
|
| September 25, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 September 25, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal |
|
| September 25, 2024 |
MATERIAL CHANGE REPORT Form 51-102F3 EX-99.1 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE September 17, 2024 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on September 17, 2024 via “GLO |
|
| September 18, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 September 18, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal |
|
| September 18, 2024 |
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025 EX-99.1 Exhibit 99.1 Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025 MONTREAL, September 17, 2024 (GLOBE NEWSWIRE) – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary suppl |
|
| July 10, 2024 |
Table of Contents Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three- and six-month periods ended May 31, 2024 and 2023 (Unaudited) Table of Contents THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated St |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 July 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executiv |
|
| July 10, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE-AND SIX-MONTH PERIODS ENDED MAY 31, 2024 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three- and six-month periods ended May 31, 2024, compared to the three- and six-month p |
|
| July 10, 2024 |
Exhibit 99.1 Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 • Q2 revenue of $22 million represents +25% growth year-over-year • Positive net income of $1 million realized with Adjusted EBITDA1 of $5.5 million • Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million Montreal, |
|
| July 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 July 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executiv |
|
| July 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended May 31, 2024. 2. No misrepresentati |
|
| July 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended May 31, 2024. 2. No mi |
|
| May 10, 2024 |
REPORT ON VOTING RESULTS ANNUAL MEETING OF SHAREHOLDERS HELD ON MAY 9, 2024 Exhibit 99.1 REPORT ON VOTING RESULTS ANNUAL MEETING OF SHAREHOLDERS HELD ON MAY 9, 2024 The Annual Meeting of Shareholders (the “Meeting”) of Theratechnologies was held online via a live audio webcast on Thursday, May 9, 2024, at 10:00 a.m. (Eastern Time). At least two shareholders and/or proxy holders were present at the Meeting, in person or by proxy, holding 30,802,072 common shares of Therate |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 May 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executive |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 May 9, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executive |
|
| May 9, 2024 |
Theratechnologies Reports on its Annual Meeting of Shareholders Exhibit 99.1 Theratechnologies Reports on its Annual Meeting of Shareholders MONTREAL, May 9, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual- |
|
| April 17, 2024 |
Theratechnologies Inc. 2015 Peel Street, Suite 1100 Montréal, Québec H3A 1T8 Theratechnologies Inc. 2015 Peel Street, Suite 1100 Montréal, Québec H3A 1T8 Canada April 17, 2024 VIA EDGAR Ms. Vanessa Robertson Division of Corporate Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 RE: Theratechnologies Inc. – Your File No. 001-35203 Ms. Robertson, This letter is being issued in response to your letter dated April 8, 2024, addressed t |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 April 15, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| April 15, 2024 |
Table of Contents Exhibit 99.2 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON THURSDAY, MAY 9, 2024 AND MANAGEMENT PROXY CIRCULAR April 8, 2024 Table of Contents NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To the shareholders of Theratechnologies Inc. (the “Corporation”): NOTICE IS HEREBY GIVEN that an annual meeting of shareholders (the “Meeting”) of the Corporation will be conducted online |
|
| April 15, 2024 |
Exhibit 99.3 Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com 000001 Mr A Sample Designation (if any) Security Class Add1 123 Add2 Holder Account Number add3 add4 add5 C1234567890 XXX add6 Fold Form of Proxy—Annual Meeting of Shareholders to be held on May 9, 2024 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. sharehold |
|
| April 15, 2024 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To the shareholders of Theratechnologies Inc. (the “Corporation”): NOTICE IS HEREBY GIVEN that an annual meeting of shareholders (the “Meeting”) of the Corporation will be conducted online only through a live audio webcast at https://meetnow.global/M7MFS6Y on Thursday, May 9, 2024, at 10:00 a.m. (Eastern Time) for the following purposes: (1) to |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 April 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| April 10, 2024 |
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 Exhibit 99.1 Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 • Q1 2024 consolidated revenue of $16.2 million • Report marks third consecutive quarter of near flat-to-positive Adjusted EBITDA • FY2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA1 in the range of $13-15 million • Acceleration of Phase 1 trial of sudocet |
|
| April 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended February 29, 2024. 2. |
|
| April 10, 2024 |
Exhibit 99.1 Interim Consolidated Financial Statements (In thousands of United States dollars) THERATECHNOLOGIES INC. Three-month periods ended February 29, 2024 and February 28, 2023 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (In thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive L |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 April 10, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| April 10, 2024 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended February 29, 2024. 2. No misreprese |
|
| April 10, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED FEBRUARY 29, 2024 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three-month period ended February 29, 2024, compared to the three-month period ended February 28, |
|
| April 5, 2024 |
Theratechnologies Appoints Elina Tea to its Board of Directors Exhibit 99.1 Theratechnologies Appoints Elina Tea to its Board of Directors Montreal, Canada – April 5, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 April 5, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executiv |
|
| March 22, 2024 |
Theratechnologies Appoints Jordan Zwick to its Board of Directors Exhibit 99.1 Theratechnologies Appoints Jordan Zwick to its Board of Directors Montreal, Canada – March 21, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 March 22, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 March 22, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| March 22, 2024 |
Theratechnologies Announces Update on its Preclinical Oncology Research Program Exhibit 99.1 Theratechnologies Announces Update on its Preclinical Oncology Research Program Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today a |
|
| March 21, 2024 |
Exhibit 99.1 Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer • Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol • First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/dose MONTREAL, March 21, 2024 – Th |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 March 21, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal executi |
|
| February 29, 2024 |
THERATECHNOLOGIES ANNOUNCES THE RESIGNATION OF ONE OF ITS DIRECTORS, MR. ALAIN TRUDEAU Exhibit 99.1 THERATECHNOLOGIES ANNOUNCES THE RESIGNATION OF ONE OF ITS DIRECTORS, MR. ALAIN TRUDEAU Montreal, Canada – February 29, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of D |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 29, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 27, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| February 27, 2024 |
Exhibit 99.1 Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA MONTREAL, February 27, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United S |
|
| February 21, 2024 |
INSIDER TRADING POLICY DATED NOVEMBER 29, 2021 Exhibit 11.2 INSIDER TRADING POLICY DATED NOVEMBER 29, 2021 TABLE OF CONTENTS Page I. INTRODUCTION AND PURPOSES 1 II. DEFINITIONS 1 III. GENERAL RESTRICTIONS APPLICABLE TO ALL THERATECHNOLOGIES PERSONNEL 2 A. Insider Trading 2 B. Confidentiality of Non-Public Information 2 C. Tipping 2 D. Consequences of Non-Compliance 3 IV. ADDITIONAL RESTRICTIONS APPLICABLE TO REPORTING INS |
|
| February 21, 2024 |
THIRD AMENDMENT TO AMENDED AND RESTATED MASTER SERVICES AGREEMENT Exhibit 4.34 THIRD AMENDMENT TO AMENDED AND RESTATED MASTER SERVICES AGREEMENT This Third Amendment to Master Services Agreement (this “Amendment”) dated December 1, 2021 (“Amendment Effective Date”) by and between Syneos Health Commercial Services, LLC (f/k/a inVentiv Commercial Services, LLC) a Syneos Health® group company (“Syneos Health”) and Theratechnologies, Inc. (“Client”). Client and Syne |
|
| February 21, 2024 |
Exhibit 4.37 DATE : MARCH 1, 2020 EMPLOYMENT CONTRACT BETWEEN: THERATECHNOLOGIES INC., corporation governed by the Business Corporations Act (Quebec), having its head office at 2015, Peel Street, 11th floor, Montreal, Province of Quebec, H3A 1T8; (the “Employer” or “Thera”) AND: PAUL LÉVESQUE, residing at (the “Executive”) WHEREAS: 1. The Employer is a publicly-listed company which condu |
|
| February 21, 2024 |
Exhibit 99.1 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance • Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 • Record quarterly revenue of $23.5 million and annual revenue of $81.8 million • Upda |
|
| February 21, 2024 |
Exhibit 4.47 [TRANSLATION] PERSONAL AND CONFIDENTIAL Friday, December 15, 2023 Jocelyn Lafond General Counsel and Corporate Secretary Theratechnologies Inc. RE: Salary Increase 2024 Dear Jocelyn, In recognition of your significant contributions this year, I am pleased to confirm that effective December 1, 2023, your gross annual salary has been increased to CA$356,723.98, which is a 3.7% increase. |
|
| February 21, 2024 |
EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES–OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Theratechnologies Inc. (the “Company”) for the fiscal year ended November 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Lévesque, President and Chie |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 21, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| February 21, 2024 |
AMENDMENT MANUFACTURE AND SUPPLY AGREEMENT Exhibit 4.27 AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENT THIS AMENDMENT (the “Amendment”) is made as of the 7th, day of January, 2020 (the “Execution Date”) BETWEEN: THERATECHNOLOGIES INC., a corporation incorporated under the laws of the Province of Québec, having its head office at 2015 Peel St., 11th floor, Montreal, Québec, H3A 1T8; (“Purchaser”) AND: JUBILANT HOLLISTERSTIER GENERAL PARTNERS |
|
| February 21, 2024 |
Exhibit 17 SUBSIDIARY GUARANTORS Issuer Number of Shares Owned Total Shares Outstanding % of Interest Pledged Certificate No. |
|
| February 21, 2024 |
Exhibit 4.31 AMENDMENT #2 TO SHARE PURCHASE AGREEMENT AMONG: TRANSFERT PLUS, L.P. AND ALIGO INNOVATION, L.P. AND BORHANE ANNABI AND RICHARD BÉLIVEAU AND CYNDIA CHARFI AND JEAN-CHRISTOPHE CURRIE AND ALAIN LAROCQUE AND MICHEL DEMEULE AND SOPHIE KOZELKO AND THERATECHNOLOGIES INC. DATED AS OF MARCH 29, 2021 THIS AMENDMENT #2 TO SHARE PURCHASE AGREEMENT dated February 25, 2019 is made as of the 31st da |
|
| February 21, 2024 |
Exhibit 4.38 EMPLOYMENT CONTRACT ENTERED INTO at the place and date of the last signature appearing on the last page. BETWEEN: THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Québec), having its head office and principal place of business at 2015 Peel Street, 5th Floor, Montréal, Province of Québec, H3A 1T8; (hereinafter “Thera”) AND: PHILIPPE DUBUC, residing and d |
|
| February 21, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EX-12.2 Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Philippe Dubuc, certify that: 1 I have reviewed this annual report on Form 20-F of Theratechnologies Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 21, 2024 |
Exhibit 4.32 CONSULTING AGREEMENT CONSULTING AGREEMENT MADE AND ENTERED INTO WITH AN EFFECTIVE DATE OF MAY 13, 2021 BETWEEN: THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec), having its principal place of business at 2015 Peel Street, 11th Floor, Montreal, Province of Québec, Canada, H3A 1T8; (hereafter “Thera”) AND: JP ARENA REGULATORY CONSULTING, LLC, a co |
|
| February 21, 2024 |
Code of Business Conduct and Ethics Exhibit 11.1 Thera technologies CODE OF BUSINESS CONDUCT & ETHICS Driving Innovation through Integrity 1. Message from the President and Chief Executive Officer 2. Purpose of the Code and its Use 2.1 Introduction 2.2 Responsibilities of Managers and Directors; Compliance Officer 2.3 Certification 2.4 Review of Code 3. Healthcare Compliance Principles 3.1 Healthcare Compliance 3.2 U.S. Pharmaceutic |
|
| February 21, 2024 |
MANUFACTURING AND SUPPLY AGREEMENT Exhibit 4.36 MANUFACTURING AND SUPPLY AGREEMENT ENTERED INTO on the 31st day of July 2023 (“Effective Date”) BETWEEN: THERATECHNOLOGIES INC., a company incorporated pursuant to the laws of the Province of Quebec, having its head office and principal place of business at 2015 Peel Street, Suite 1100 in the City of Montreal, Province of Quebec, Canada, H3A 1T8 (hereinafter referred to as “Thera”) AN |
|
| February 21, 2024 |
Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 (“Exchange Act”) As of the date of the Annual Report on Form 20-F of which this Exhibit 2.3 is a part, Theratechnologies Inc. (“Company”, “Corporation”, “we” or “us”) had the following securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Nam |
|
| February 21, 2024 |
Amendment No. 2 to Amended and Restated Statement of Work #2 Exhibit 4.35 Amendment No. 2 to Amended and Restated Statement of Work #2 This Amendment No. 2 to the Amended and Restated Statement of Work #2 (“Amendment #1”) is entered into as of the last date signed (the “Amendment #2 Effective Date”) pursuant to and shall be governed by the terms and conditions set forth in that certain Amended and Restated Master Services Agreement by and between Theratechn |
|
| February 21, 2024 |
THERATECHNOLOGIES INC. RESTATEMENT CLAWBACK POLICY Adopted on November 30, 2023 Exhibit 97.1 THERATECHNOLOGIES INC. RESTATEMENT CLAWBACK POLICY Adopted on November 30, 2023 This Restatement Clawback Policy (this “Policy”) has been established and adopted by the Board of Directors (the “Board”) of Theratechnologies Inc. (the “Company”) and will be administered by the Compensation Committee (the “Committee”) of the Board. Defined terms used in this Policy shall have the respect |
|
| February 21, 2024 |
Exhibit 4.33 AMENDMENT #3 to Amended and Restated Distribution and Marketing Agreement (the “Agreement”) TERM SHEET Parties TaiMed and Thera. Definition of “IM Mode of Administration” Article 1 of the Agreement is hereby amended by adding a definition of “IM Mode of Administration” and “Activities” which shall read as follows: “IM Mode of Administration” means the intra-muscular injection of the P |
|
| February 21, 2024 |
Exhibit 4.46 [TRANSLATION] PERSONAL AND CONFIDENTIAL July 27, 2023 Jocelyn Lafond RE: Amendment to your Employment Contract Dear Jocelyn, Following the decision of the Board of Directors to propose amendments to management employment contracts in order to update them in accordance with current legal principles and to harmonize the terms and conditions of employment contracts of exec |
|
| February 21, 2024 |
Exhibit 4.39 PERSONAL AND CONFIDENTIAL July 27, 2023 Philippe Dubuc RE: Amendment to your Employment Contract Dear Philippe, Following the decision of the Board of Directors to propose amendments to management employment contracts in order to update them in accordance with current legal principles and to harmonize the terms and conditions of employment contracts of executive office |
|
| February 21, 2024 |
Exhibit 4.26 AMENDMENT #2 This AMENDMENT #2 TO AMENDED AND RESTATED DISTRIBUTION AND MARKETING AGREEMENT (the “Amendment”), effective as of November 5, 2019 (the “Amendment Effective Date”), is made by and between TAIMED BIOLOGICS INC., a Taiwan corporation with the registered company address at 3F, No. 607, Ruiguang Road, Neihu District, Taipei City 11492, Taiwan, R.O.C. (“TaiMed”), and THERATECH |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 21, 2024 |
Exhibit 4.43 PERSONAL AND CONFIDENTIAL Montreal, July 31, 2023 John Leasure RE: Amendment to your Employment Agreement Dear John: Further the decision of the board of directors of Theratechnologies Inc. (“Thera”) to harmonize the terms and conditions of all of the employment agreements of the executive officers related to a termination without a serious reason and a termination in th |
|
| February 21, 2024 |
THERATECHNOLOGIES INC. (the “Corporation”) BY-LAW NO. 4 ADVANCE NOTICE BY-LAW Exhibit 1.3 THERATECHNOLOGIES INC. (the “Corporation”) BY-LAW NO. 4 ADVANCE NOTICE BY-LAW Introduction The Corporation is committed to (i) facilitating an orderly and efficient process for holding annual general meetings and, when the need arises, special meetings of its shareholders; (ii) ensuring that all shareholders receive adequate advance notice of the director nominations and sufficient inf |
|
| February 21, 2024 |
AMENDMENT MANUFACTURE AND SUPPLY AGREEMENT Exhibit 4.29 AMENDMENT TO MANUFACTURE AND SUPPLY AGREEMENT THIS AMENDMENT (the “Amendment”) is made as of the 1st, day of January, 2021 (the “Execution Date”) BETWEEN: THERATECHNOLOGIES INC., a corporation incorporated under the laws of the Province of Québec, having its head office at 2015 Peel St., 11th floor, Montreal, Québec, H3A 1T8; (“Purchaser”) AND: JUBILANT HOLLISTERSTIER GENERAL PARTNERS |
|
| February 21, 2024 |
FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE Exhibit 4.30 FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This is a first amendment to the amended and restated exclusive license agreement dated February 25, 2019 (the “First Amendment”). BETWEEN : TRANSFERT PLUS, LIMITED PARTNERSHIP, a limited partnership duly constituted under the laws of the Province of Quebec, having its principal place of business at 1405, boulevar |
|
| February 21, 2024 |
EXHIBIT 4.41 [TRANSLATION] PERSONAL AND CONFIDENTIAL July 27, 2023 Christian Marsolais RE: Amendment to your restated and amended Employment Contract Dear Christian, Following the decision of the Board of Directors to propose amendments to management employment contracts in order to update them in accordance with current legal principles and to harmonize the terms and conditio |
|
| February 21, 2024 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 4.40 AMENDED AND RESTATED EMPLOYMENT AGREEMENT ENTERED INTO at the place and date of the last signature appearing on the last page. BETWEEN: THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Québec), having its head office and principal place of business at 2310 Alfred-Nobel Boulevard, Montréal, Province of Québec, H4S 2B4; (hereinafter “Thera”) AND: CHRISTIA |
|
| February 21, 2024 |
Exhibit 4.42 THIS EMPLOYMENT AGREEMENT is made as of the 6th day of January 2023 with an effective date as of April 11, 2022 (the “Effective Date”) BETWEEN: THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec), having its head office at 2015 Peel Street, 11th floor, Montreal, Province of Quebec, H3A 1T8; (the “Company”) AND: JOHN O. LEASURE, residing at |
|
| February 21, 2024 |
Exhibit 4.44 [TRANSLATION] EMPLOYMENT AGREEMENT ENTERED INTO at the place and date of the last signature appearing on the last page. BETWEEN: THERATECHNOLOGIES INC., a company legally constituted under the Companies Act (Québec), having its head office and principal place of business at 2310 Alfred-Nobel Blvd., Montréal, Province of Québec, H3S 2A4; (hereinafter “Thera”) AND: JOCELYN LAFOND, res |
|
| February 21, 2024 |
Exhibit 4.45 [TRANSLATION] PERSONAL AND CONFIDENTIAL June 28, 2012 Jocelyn Lafond RE: Amendment to your Employment Contract Dear Jocelyn, Following the decision of the Board of Directors to propose amendments to management employment contracts in the event of any member(s) of management being dismissed without a serious reason following an acquisition of control of Theratechnologie |
|
| February 21, 2024 |
SHARE OPTION PLAN EFFECTIVE DATE : MAY 9, 2023 Exhibit 2.2 SHARE OPTION PLAN EFFECTIVE DATE : MAY 9, 2023 1. PURPOSE OF THE PLAN The Share Option Plan (the “Plan”) is intended to attract, retain and motivate individuals to the success of Theratechnologies Inc., on a consolidated basis (the “Corporation”), to align those individuals’ interests with those of the Corporation’s shareholders and to allow these individuals to participate in the incr |
|
| February 21, 2024 |
CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 EX-12.1 Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Paul Lévesque, certify that: 1. I have reviewed this annual report on Form 20-F of Theratechnologies Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 21, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Theratechnologies Inc. |
|
| February 21, 2024 |
FIRST AMENDMENT TO THE AMENDED & RESTATED LICENSE AGREEMENT MGH Agreement No. 2020-1109 Exhibit 4.28 FIRST AMENDMENT TO THE AMENDED & RESTATED LICENSE AGREEMENT MGH Agreement No. 2020-1109 This FIRST AMENDMENT to the AMENDED & RESTATED LICENSE AGREEMENT (“First Amendment”) is made as of the 15th day of April, 2020 (“First Amendment Effective Date”) between Theratechnologies, Inc., a Québec company, having a principal place of business at 2015 Peel Street, 11th Floor, Montréal, Québec |
|
| February 21, 2024 |
THERATECHNOLOGIES INC. AMENDED AND RESTATED BY-LAW NO. 3 GENERAL BY-LAWS Exhibit 1.2 THERATECHNOLOGIES INC. AMENDED AND RESTATED BY-LAW NO. 3 GENERAL BY-LAWS INTERPRETATION 1. Definitions. The definitions set out in the Business Corporations Act (CQLR., c. S-31.1), and in any amendment or successor act thereto (collectively, the “Act”), shall apply to the terms used in these General By-Laws. 2. Computation of Time. The computation of time or any period in days shall |
|
| February 21, 2024 |
EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES–OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Theratechnologies Inc. (the “Company”) for the fiscal year ended November 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philippe Dubuc, Senior Vice Presi |
|
| February 15, 2024 |
Exhibit 99.1 Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer • Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, February 15, 2024 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 15, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| February 14, 2024 |
THERATECHNOLOGIES INC / Nantahala Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm243309d34sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* THERATECHNOLOGIES INC. (Name of Issuer) Common Shares (Title of Class of Securities) 88338H704 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 7, 2024 |
THERATECHNOLOGIES INC / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 THERATECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 88338H704 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 6, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| February 6, 2024 |
Exhibit 99.1 Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update MONTREAL, February 6, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report f |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 February 1, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| February 1, 2024 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE January 24, 2024 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on January 24, 2024 via “GLOBE NEWSWIRE” |
|
| January 24, 2024 |
Exhibit 99.1 Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA • FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity • CRL does not impact commercial availability of EGRIFTA SV®, the F4 formulation of tesamorelin, the only medication approved in the U.S. for t |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 January 24, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 January 23, 2024 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| January 23, 2024 |
Exhibit 99.1 Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic Licence Application ● FDA continues to review the file past the Prescription Drug User Fee Act goal date of January 22, 2024 MONTREAL, January 23, 2024 (GLOBE NEWSWIRE) - Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the de |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| January 2, 2024 |
Theratechnologies Inc. 2015 Peel Street, Suite 1100 Montréal, Québec H3A 1T8 CORRESP 1 filename1.htm Theratechnologies Inc. 2015 Peel Street, Suite 1100 Montréal, Québec H3A 1T8 Canada January 2, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Daniel Crawford Re: Theratechnologies Inc. Registration Statement on Form F-3 Filed on December 21, 2023 File No. 333-276196 Ladies and Gentlemen: P |
|
| December 21, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) THERATECHNOLOGIES INC. |
|
| December 21, 2023 |
As filed with the Securities and Exchange Commission on December 21, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 21, 2023 Registration No. |
|
| December 21, 2023 |
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Exhibit 99.1 Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Montreal, Quebec – December 21, 2023 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base s |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 21, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| December 13, 2023 |
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose Exhibit 99.1 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose • Updated label means new Trogarzo® patients no longer require initiation of treatment by 30-minute infusion • Complete IV push method enables easier and more convenient administration of Trogarzo® for heavily treatment-experienced adults with HIV This news release constitutes a “designa |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 December 13, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exec |
|
| November 29, 2023 |
CA88338H7040 / THERATECHNOLOGIES INC / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 THERATECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 88338H704 (CUSIP Number) October 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ |
|
| November 28, 2023 |
SC 13D 1 ea189157-13dsoleustheratech.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.) THERATECHNOLOGIES INC. (Name of Issuer) Common Stock (Title of Class of Securities) 88338H704 (CUSIP Number) Soleus Capital Master Fund, L.P. 104 Field Point Road, 2nd Floor Greenwich, CT 06830 Attn: Ste |
|
| November 28, 2023 |
EX-99.1 2 ea189157ex99-1theratech.htm JOINT FILING AGREEMENT, DATED NOVEMBER 28, 2023, AMONG THE REPORTING PERSONS EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common |
|
| November 13, 2023 |
THTX / Theratechnologies Inc. / Investissement Quebec - SCHEDULE 13D Activist Investment SC 13D 1 ea188073-13dinvesttheratech.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* THERATECHNOLOGIES INC. (Name of Issuer) Common Shares (Title of Class of Securities) 88338H100 (CUSIP Number) Thomas M. Rose Troutman Pepper Hamilton Sanders LLP 401 9th Street, N.W., Suite 1000 Washin |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 November 6, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 November 6, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| November 6, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street Suite 1100 Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE October 31, 2023 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on October 31, 2023 via “GLOBE NEWSWIRE” |
|
| November 6, 2023 |
THERATECHNOLOGIES INC. - and - INVESTISSEMENT QUÉBEC INVESTOR RIGHTS AGREEMENT October 31, 2023 Exhibit 99.1 [Unofficial Translation. In case of discrepancy, the signed French version dated October 31, 2023 shall take precedence] Execution Version THERATECHNOLOGIES INC. - and - INVESTISSEMENT QUÉBEC INVESTOR RIGHTS AGREEMENT October 31, 2023 THIS AGREEMENT is made as of October 31, 2023. BETWEEN: THERATECHNOLOGIES INC, a business corporation governed by the Business Corporations Act (Québec) |
|
| November 3, 2023 |
Exhibit 99.2 May 15, 2023 Via EMAIL MAM Tiger Lender LLC 1 Bryant Park 38th fl. New York, NY 10036 Attn: Nishi Kapoor; Finney Simon Marathon Healthcare Finance Fund, L.P. 1 Bryant Park 38th fl. New York, NY 10036 Attn: Nishi Kapoor; Finney Simon Re: Credit Agreement Amendment for Q2 2023 Minimum Net Revenues Ladies and gentlemen: Reference is made to that certain Credit Agreement dated as of July |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 November 3, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| November 3, 2023 |
AMENDED AND RESTATED FOURTH AMENDMENT TO CREDIT AGREEMENT Exhibit 99.5 AMENDED AND RESTATED FOURTH AMENDMENT TO CREDIT AGREEMENT This AMENDED AND RESTATED FOURTH AMENDMENT TO CREDIT AGREEMENT (this “A&R Amendment”) is made and entered into as of September 21, 2023 by and among THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec) (the “Borrower”), and the lenders party hereto (the “Lenders”), which constitute the Requir |
|
| November 3, 2023 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 99.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of February 27, 2023 by and among THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec) (the “Borrower”), and the lenders party hereto (the “Lenders”), which constitute the Required Lenders. WHEREAS, the Borrow |
|
| November 3, 2023 |
FOURTH AMENDMENT TO CREDIT AGREEMENT Exhibit 99.4 Execution Version FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of July 28, 2023 by and among THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec) (the “Borrower”), and the lenders party hereto (the “Lenders”), which constitute the Required Lenders. WHEREAS, the Borrower |
|
| November 3, 2023 |
Exhibit 99.3 July 10, 2023 Via EMAIL MAM Tiger Lender LLC 1 Bryant Park 38th fl. New York, NY 10036 Attn: Nishi Kapoor; Finney Simon Marathon Healthcare Finance Fund, L.P. 1 Bryant Park 38th fl. New York, NY 10036 Attn: Nishi Kapoor; Finney Simon Re: Credit Agreement Amendment for Liquidity Covenant Ladies and gentlemen: Reference is made to that certain Credit Agreement dated as of July 20, 2022, |
|
| November 3, 2023 |
FIFTH AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO WARRANTS Exhibit 99.6 Execution Version FIFTH AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO WARRANTS This FIFTH AMENDMENT TO CREDIT AGREEMENT AND AMENDMENT TO WARRANTS (this “Amendment”) is made and entered into as of October 13, 2023 by and among THERATECHNOLOGIES INC., a corporation governed by the Business Corporations Act (Quebec) (the “Borrower”), and the lenders party hereto (the “Lenders”), which c |
|
| October 31, 2023 |
Exhibit 99.1 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Montreal, Quebec, October 31, 2023 – Theratechnologies Inc. (“The |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 31, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 27, 2023 |
Exhibit 99.1 THERATECHNOLOGIES INC. 12,500,000 Shares of Common Stock (no par value per share) Underwriting Agreement October 25, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Theratechnologies Inc., a corporation formed under the Companies Act (Québec) and continued under the Business Corporations Act (Québec) (the “Company”), proposes to issue and sell to |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 26, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 27, 2023 |
Table of Contents Filed Pursuant to General Instruction II.L of Form F-10; File No. 333-261289 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the accompanying short form base shelf prospectus dated December 14, 2021 to which it relates, as amended or supplemented, and each documen |
|
| October 26, 2023 |
Exhibit 99.1 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common shares priced at US$1.00 per share Montreal, Quebec, Octob |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): Theratechnologies Inc. B. (1) This is [check one]: ☒ an original filing for the Filer ☐ an amended filing for the Filer (2) Check the following box if you are filing the Form F-X in paper in accordance wit |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 26, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 26, 2023 |
Subject to completion, dated October 25, 2023 Table of Contents Filed Pursuant to General Instruction II.L of Form F-10; File No. 333-261289 Subject to completion, dated October 25, 2023 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This preliminary prospectus supplement, together with the accompanying short form base shelf prospectus dated December 14, 2021 to whic |
|
| October 26, 2023 |
Exhibit 99.1 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Montreal, Quebec, October 25, 2023 – Theratechnologies Inc. (“Theratechnologies” |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 25, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 24, 2023 |
Theratechnologies Announces Operational Update Exhibit 99.1 Theratechnologies Announces Operational Update This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Montreal, Canada – October 24, 2023 – Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharma |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 24, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 24, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 ITEM 1 - NAME AND ADDRESS OF COMPANY THERATECHNOLOGIES INC. (“Theratechnologies”, “we” or the “Company”) 2015 Peel Street 11th Floor Montréal, Québec Canada H3A 1T8 ITEM 2 - DATE OF MATERIAL CHANGE October 24, 2023 ITEM 3 - NEWS RELEASE A news release describing this material change was issued by the Company on October 24, 2023 via “GLOBE NEWSWIRE” |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 24, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 October 16, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal execu |
|
| October 16, 2023 |
Exhibit 99.1 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon • Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million • Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant • Deleted Prohibition Against Having a Going C |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Lévesque, President and Chief Executive Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended August 31, 2023. 2. No misrepresent |
|
| September 26, 2023 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Philippe Dubuc, Senior Vice President and Chief Financial Officer of Theratechnologies Inc., certify the following: 1. Review: I have reviewed the interim financial statements and interim MD&A, (together, the “interim filings”) of Theratechnologies Inc. (the “issuer”) for the interim period ended August 31, 2023. 2. No |
|
| September 26, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE-AND NINE-MONTH PERIODS ENDED AUGUST 31, 2023 The following Management’s Discussion and Analysis (“MD&A”) provides Management’s point of view on the financial position and results of operations of Theratechnologies Inc., on a consolidated basis, for the three- and nine-month periods ended August 31, 2023, compared to the three- and nin |
|
| September 26, 2023 |
Exhibit 99.1 Interim Consolidated Financial Statements (in thousands of United States dollars) THERATECHNOLOGIES INC. Three- and nine-month periods ended August 31, 2023 and 2022 (Unaudited) THERATECHNOLOGIES INC. Table of Contents (in thousands of United States dollars) (Unaudited) Page Interim Consolidated Statements of Financial Position 1 Interim Consolidated Statements of Comprehensive Loss 2 |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 September 26, 2023 Commission File Number 001-35203 THERATECHNOLOGIES INC. (Translation of registrant’s name into English) 2015 Peel Street, Suite 1100 Montréal, Québec, Canada H3A 1T8 (Address of principal exe |
